BRCA1-Based Breast or Ovarian Cancer Prevention Agents

Track Code: 
08KU009M
Summary: 

This invention is aimed at delaying the tumor growth in breast and ovarian cancers by increasing BRCA1 protein expression.

Overview: 

Currently, breast cancer is treated by surgery, radiation therapy, chemotherapy, targeted therapy, and hormonal therapy.

Hormonal therapy is an option for anyone with hormone receptor positive breast cancer. About 60% of breast cancers are hormone receptor positive. However, there are several side effects with hormonal therapy, including uterine cancer and weakening of the bones.

Current targeted therapies only work for HER2 positive breast cancers. However, only 15 to 20% of women with breast cancer have HER2-positive tumors.

This invention is a selection of agents that target the tumor suppressor gene, BRCA1. BRCA1 is responsible for many breast and ovarian cancers. Increasing BRCA1 protein expression will prevent or delay the onset of breast or ovarian tumors. BRCA1 is mutated in 5-10% of all breast cancers. However, these agents also target the 90% of sporadic breast cancers that have a normal BRCA1 gene whose protein expression is decreased. The prevention agents can be administered through any medically acceptable mode in either a localized or systemic approach.

Applications: 

This invention is aimed at delaying the tumor growth in breast and ovarian cancers by increasing BRCA1 protein expression.

How it works: 

Current targeted therapies only work for HER2 positive breast cancers. However, only 15 to 20% of women with breast cancer have HER2-positive tumors.

Licensing Associate: 
Matthew Koenig, JD · mekoenig@ku.edu · 785-864-1774
Category(s): 
Subcategory(s): 
Keyword(s): 
Inventor(s): 
Frank Schoenen
Gerald Lushington
Jeffrey Aube
Roy Jensen
Lisa Harlan-Williams
Patent(s): 
US 2012/0259005
CA 2705812
EP 2214664
Status: 
Patented